Who We Are
Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.
Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.
Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.
Key Issues
Causes We Care About, and So Should You!
HIV
Promote necessary funding, programs, and policies to end the HIV epidemic in the United States
HEPATITIS
Promote necessary funding, programs, and policies to end viral hepatitis in the United States
HEALTHCARE ACCESS
Promote necessary funding, programs, and policies to end viral hepatitis in the United States
Facebook posts by @HIV+Hep
The HIV and Hepatitis Policy Institute in Axios: “In the U.S., most private health #insurance plans must cover #PrEP without #costsharing, but more federal guidance is needed to make sure plans cover both pills & injectables without #priorauth”: bit.ly/4eVnlg9
Biden-Harris Administration Sides with Insurers & Fails to Issue Promised Copay Assistance Rule to Lower Patient Costs for Prescription Drugs.
hivhep.org
Washington DC... In a shock to patients who are struggling to afford their prescription medications, the Biden-Harris administration has failed—again—to take steps to lower how much Americans pay ...
See our recent opinion piece in the Blade urging the Biden Harris Administration to issue guidance to insurers to ensure that long-acting PrEP is covered without co-pays just like daily oral PrEP.
Biden-Harris must ensure access to HIV prevention drugs
www.washingtonblade.com
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are hitting the . . .
HIV+Hepatitis Policy Institute, an advocacy group, criticized the proposed rule’s impact on patients, saying the government is still letting pharmacy benefit managers (PBMs) profit from copay assistance. The rule included no requirements that copay assistance be counted as part of patient cost-sharing, and no provision closing an essential health benefits loophole.![]()
![]()
“Coming from an administration that prides itself on supporting patients and lowering their prescription drug costs, this is a huge disappointment,” said Carl Schmid, executive director at the institute. “While they have gone on record that they will issue these rules, the clock is ticking and there isn’t much time left.”![]()
CMS proposes risk adjustment changes, broker fraud crackdown for 2026 plan year
www.fiercehealthcare.com
A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the ins...
Surprise! The Copay for PrEP Just Disappeared
www.medpagetoday.com
Medicare's decision to cover all PrEP drugs under Part B has unexpected benefit for enrollees